What is Trince?
Headquartered in Ghent, Belgium, Trince is a biotechnology firm specializing in the insertion of genetic material into cells. The company's focus on advanced genetic engineering positions it at the forefront of therapeutic innovation, aiming to develop novel treatments for a range of conditions. This strategic investment is expected to fuel further research and development, enhancing Trince's capabilities in cell-based therapies.
How much funding has Trince raised?
Trince has raised a total of $4.5M across 1 funding round:
Unspecified
$4.5M
Unspecified (2021): $4.5M with participation from Qbic II and Novalis Biotech Acceleration
Key Investors in Trince
Qbic II
Qbic II is an investment fund likely focused on early-stage life sciences companies, providing crucial capital for technological development and market entry.
Novalis Biotech Acceleration
Novalis Biotech Acceleration is a venture capital firm specializing in supporting and scaling innovative biotechnology startups, offering both financial backing and strategic guidance.
What's next for Trince?
With this substantial capital infusion, Trince is poised for accelerated growth and expansion. The company is likely to focus on advancing its pipeline candidates through preclinical and clinical trials, potentially forging strategic partnerships to broaden its market reach. The enterprise-level backing suggests confidence from investors in Trince's technology and its potential to disrupt the biotechnology landscape, paving the way for future commercialization efforts and further funding rounds.
See full Trince company page
